{"transactions":[{"id":885009,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T18:40:45.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001706301-26-000002","document":"wk-form4_1771976443.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000170630126000002/wk-form4_1771976443.xml","form_type":"4"}},{"id":1111733,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T12:05:49.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000064","document":"wk-form4_1749830742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000140464425000064/wk-form4_1749830742.xml","form_type":"4"}},{"id":1117960,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-09T18:57:07.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":5239,"price":1.75,"value":9168.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":109135,"source":{"system":"sec-edgar","filing":"0000950170-25-083952","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017025083952/ownership.xml","form_type":"4"}},{"id":1179668,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T11:56:20.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":84000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0000950170-25-050098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017025050098/ownership.xml","form_type":"4"}},{"id":1179667,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-03T11:56:20.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":114374,"source":{"system":"sec-edgar","filing":"0000950170-25-050098","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017025050098/ownership.xml","form_type":"4"}},{"id":1473215,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T16:27:11.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":10450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer."}],"balance_after":10450,"derivative":{"exercise_price":1.4,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001415889-24-017641","document":"form4-06202024_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000141588924017641/form4-06202024_080606.xml","form_type":"4"}},{"id":1473214,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T16:27:11.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":14100,"source":{"system":"sec-edgar","filing":"0001415889-24-017641","document":"form4-06202024_080606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000141588924017641/form4-06202024_080606.xml","form_type":"4"}},{"id":1477340,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T14:36:03.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000068","document":"wk-form4_1718649355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000140464424000068/wk-form4_1718649355.xml","form_type":"4"}},{"id":1549773,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T20:47:43.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":242875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":242875,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":242875},"source":{"system":"sec-edgar","filing":"0000950170-24-041527","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017024041527/ownership.xml","form_type":"4"}},{"id":1549772,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-03T20:47:43.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":57763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":100374,"source":{"system":"sec-edgar","filing":"0000950170-24-041527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017024041527/ownership.xml","form_type":"4"}},{"id":1675244,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T16:28:37.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":20900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 12 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer."}],"balance_after":20900,"derivative":{"exercise_price":9.74,"expiration_date":"2034-01-18","underlying":"Common Stock","underlying_shares":20900},"source":{"system":"sec-edgar","filing":"0001415889-24-001604","document":"form4-01192024_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000141588924001604/form4-01192024_090131.xml","form_type":"4"}},{"id":1675243,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-19T16:28:37.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in full on January 18, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":11800,"source":{"system":"sec-edgar","filing":"0001415889-24-001604","document":"form4-01192024_090131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000141588924001604/form4-01192024_090131.xml","form_type":"4"}},{"id":1676435,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T18:56:12.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017024005537/ownership.xml","form_type":"4"}},{"id":1860599,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T16:26:27.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.79,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-035861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919123035861/doc4.xml","form_type":"4"}},{"id":1889109,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-17T21:08:14.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":32400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 36 equal monthly installments beginning on June 16, 2023, subject to the reporting person's continued service with the Issuer."}],"balance_after":32400,"derivative":{"exercise_price":8.51,"expiration_date":"2033-05-16","underlying":"Common Stock","underlying_shares":32400},"source":{"system":"sec-edgar","filing":"0001415889-23-008244","document":"form4-05182023_010506.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000141588923008244/form4-05182023_010506.xml","form_type":"4"}},{"id":1889108,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-17T21:08:14.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":7200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs will vest in three equal annual installments, with the first installment vesting on May 16, 2024, the second installment vesting on May 16, 2025 and the third installment vesting on May 16, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer).  Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008244","document":"form4-05182023_010506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000141588923008244/form4-05182023_010506.xml","form_type":"4"}},{"id":2052482,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-18T20:03:40.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments following the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-004734","document":"tm233829-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000110465923004734/tm233829-1_4seq1.xml","form_type":"4"}},{"id":2253564,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-27T16:01:46.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date."}],"balance_after":20000,"derivative":{"exercise_price":8.31,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-065863","document":"tm2214526-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000110465922065863/tm2214526-6_4seq1.xml","form_type":"4"}},{"id":2270412,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-16T18:24:56.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.07,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-029324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919122029324/doc4.xml","form_type":"4"}},{"id":2691364,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T18:43:34.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":18000,"derivative":{"exercise_price":35.23,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-036663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121036663/doc4.xml","form_type":"4"}},{"id":2714571,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T17:37:59.000Z","date":"2021-05-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":11.4,"expiration_date":"2031-05-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-032401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121032401/doc4.xml","form_type":"4"}},{"id":2863490,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested.  It vested in accordance with the following schedule: the shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":3600,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":3700},"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":2863489,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested.  It vested in accordance with the following schedule: the shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":7300,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":4700},"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":2863488,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":3700,"price":25.09,"value":92833.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":2863487,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":3700,"price":6.98,"value":25826.0,"ownership":{"direct":true},"balance_after":3700,"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":2863486,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":400,"price":26.04,"value":10416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $26.03 to $26.08, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":2863485,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":4300,"price":25.42,"value":109306.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.01 to $25.93, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":2863484,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T18:36:55.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":4700,"price":6.98,"value":32806.0,"ownership":{"direct":true},"balance_after":4700,"source":{"system":"sec-edgar","filing":"0001209191-21-010401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919121010401/doc4.xml","form_type":"4"}},{"id":3130753,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T18:16:37.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) May 28, 2021, or (ii) the date of the 2021 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":15000,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-033022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919120033022/doc4.xml","form_type":"4"}},{"id":3158157,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-07T16:26:43.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":12.84,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-027683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919120027683/doc4.xml","form_type":"4"}},{"id":3393721,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-15T16:45:19.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":22000,"derivative":{"exercise_price":2.82,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-19-025573","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000089924319025573/doc4.xml","form_type":"4"}},{"id":3494339,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T18:28:05.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) June 7, 2020, or (ii) the date of the 2020 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-036204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919119036204/doc4.xml","form_type":"4"}},{"id":3897000,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-12T18:43:03.000Z","date":"2018-05-29","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-037312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919118037312/doc4.xml","form_type":"4"}},{"id":3994770,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-15T19:26:52.000Z","date":"2017-12-15","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment to the previously filed Form 4 is being filed to correct a typographical error in the exercise price of the option to purchase common stock of the Issuer held by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest in 36 equal monthly installments from the vesting commencement date of December 12, 2017."}],"balance_after":24000,"derivative":{"exercise_price":18.99,"expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-18-019990","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919118019990/doc4a.xml","form_type":"4/A","original_submission_date":"2017-12-19"}},{"id":4126630,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-12-19T20:30:48.000Z","date":"2017-12-15","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 36 equal monthly installments from the vesting commencement date of December 12, 2017."}],"balance_after":24000,"derivative":{"exercise_price":17.57,"expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-17-066553","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000120919117066553/doc4.xml","form_type":"4"}},{"id":4313738,"issuer":{"id":2375,"kind":"organization","name":"PROTHENA CORP PUBLIC LTD CO","symbol":"PRTA"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-05-18T16:08:00.000Z","date":"2017-05-16","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on May 16, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":56.37,"expiration_date":"2027-05-16","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-17-013685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000089924317013685/doc4.xml","form_type":"4"}}]}